Orchestra BioMed (NASDAQ:OBIO – Get Free Report) and Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.
Risk and Volatility
Orchestra BioMed has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Senseonics Holdings, Inc. Common Stock has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Valuation and Earnings
This table compares Orchestra BioMed and Senseonics Holdings, Inc. Common Stock”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orchestra BioMed | $33.48 million | 10.91 | -$52.70 million | ($0.85) | -7.15 |
| Senseonics Holdings, Inc. Common Stock | $35.26 million | 11.36 | -$69.11 million | ($2.23) | -4.30 |
Orchestra BioMed has higher earnings, but lower revenue than Senseonics Holdings, Inc. Common Stock. Orchestra BioMed is trading at a lower price-to-earnings ratio than Senseonics Holdings, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Orchestra BioMed and Senseonics Holdings, Inc. Common Stock, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orchestra BioMed | 1 | 0 | 7 | 0 | 2.75 |
| Senseonics Holdings, Inc. Common Stock | 1 | 1 | 4 | 0 | 2.50 |
Orchestra BioMed presently has a consensus target price of $13.17, indicating a potential upside of 116.56%. Senseonics Holdings, Inc. Common Stock has a consensus target price of $17.20, indicating a potential upside of 79.54%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Senseonics Holdings, Inc. Common Stock.
Insider & Institutional Ownership
53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 12.4% of Senseonics Holdings, Inc. Common Stock shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Comparatively, 4.7% of Senseonics Holdings, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Orchestra BioMed and Senseonics Holdings, Inc. Common Stock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orchestra BioMed | -184.60% | -149.61% | -54.15% |
| Senseonics Holdings, Inc. Common Stock | -225.09% | -165.80% | -80.14% |
Summary
Orchestra BioMed beats Senseonics Holdings, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
